<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091217</url>
  </required_header>
  <id_info>
    <org_study_id>ML41186</org_study_id>
    <nct_id>NCT04091217</nct_id>
  </id_info>
  <brief_title>Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma</brief_title>
  <official_title>Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of atezolizumab in combination with&#xD;
      bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into 2 stages. Stage I of the study is completed when 22 patients with&#xD;
      measurable disease have been enrolled and completed ORR evaluation. If the number of&#xD;
      responders in Stage I is more than 3, another 16 patients may be enrolled to Stage II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 33 months</time_frame>
    <description>ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions &gt;= 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 33 months</time_frame>
    <description>PFS is defined as the time from the date of first treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 33 months</time_frame>
    <description>OS is defined as the time from the date of first treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>Up to approximately 33 months</time_frame>
    <description>DOR is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 33 months</time_frame>
    <description>DCR is defined as the sum of a complete or partial response or stable disease rates as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 33 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1200 mg will be administered intravenously every 3 weeks.</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unresectable locally advanced(stage III) or metastatic(Stage&#xD;
             IV) mucosal melanoma&#xD;
&#xD;
          -  May have received prior systemic treatment or treatment naive at enrollment&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Negative HIV test at screening&#xD;
&#xD;
          -  Negative hepatitis B surface antigen test at screening&#xD;
&#xD;
          -  Negative hepatitis B core antibody at screening, or positive total HBcAb test followed&#xD;
             by quantitative hepatitis B virus DNA&lt;500 IU/mL at screening.&#xD;
&#xD;
          -  Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody&#xD;
             test followed by a negative HCV RNA test at screening&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods, and agreement to refrain from&#xD;
             donating eggs&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agreement to refrain from donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or actively progressing central nervous system (CNS) metastases&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency, including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome,&#xD;
             or multiple sclerosis, with the following exceptions: 1) Patients with a history of&#xD;
             autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible&#xD;
             for the study. 2) Patients with controlled Type 1 diabetes mellitus who are on an&#xD;
             insulin regimen are eligible for the study. 3) Patients with eczema, psoriasis, lichen&#xD;
             simplex chronicus, or vitiligo with dermatologic manifestations only are eligible for&#xD;
             the study provided all of following conditions are met: (i) Rash must cover &lt; 10% of&#xD;
             body surface area (ii) Disease is well controlled at baseline and requires only&#xD;
             low-potency topical corticosteroids (iii) No occurrence of acute exacerbations of the&#xD;
             underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate,&#xD;
             retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral&#xD;
             corticosteroids within the previous 12 months&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography (CT) scan&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Significant cardiovascular disease (such as New York Heart Association Class II or&#xD;
             greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3&#xD;
             months prior to initiation of study treatment, unstable arrhythmia, or unstable angina&#xD;
&#xD;
          -  History of malignancy other than melanoma within 5 years prior to screening, with the&#xD;
             exception of malignancies with a negligible risk of metastasis or death, such as&#xD;
             adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,&#xD;
             localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug, may affect&#xD;
             the interpretation of the results, or may render the patient at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Current treatment with anti-viral therapy for HBV&#xD;
&#xD;
          -  Current, recent (within 28 days prior to initiation of study treatment) or planned&#xD;
             treatment with any other investigational agent or participation in another clinical&#xD;
             study with anti-cancer therapeutic intent&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment&#xD;
             or within 5 months after the final dose of atezolizumab, 6 months after the final dose&#xD;
             of bevacizumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Center; Renal Cancer And Melanoma Department.</name>
      <address>
        <city>Beijing City</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou City</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Zhejiang</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

